NuSH-Based Therapy
Semaglutide 2.4 mg once weekly in STEP 1 produced an average 14.9% weight reduction over 68 weeks. Tirzepatide 15 mg once weekly for 72 weeks produced weight reductions of up to 20% in adults with obesity. Representative NuSH-based agents…
1 sources - 7 claims
Semaglutide 2.4 mg once weekly in STEP 1 produced an average 14.9% weight reduction over 68 weeks. Tirzepatide 15 mg once weekly for 72 weeks produced weight reductions of up to 20% in adults with obesity. Representative NuSH-based agents include semaglutide, tirzepatide, and retatrutide. Clinical trials show substantial weight loss with NuSH-based therapies, but real-world uncertainties remain. NuSH-based therapies mimic or enhance hormones released in response to nutrient intake. NuSH-based therapies target regulators including GLP-1, GIP, and glucagon to coordinate appetite, glucose homeostasis, and energy expenditure. Their anti-obesity effects involve insulin modulation, delayed gastric emptying, appetite signalling suppression, and adipose tissue lipolysis.